Quarterly Update - Q1 2026 Peptide News
The start of 2026 has shown that the "Peptide Renaissance" is only accelerating. From the landmark approval of the first oral peptide for psoriasis to the massive expansion of the GLP-1 landscape, synthetic peptides continue to move from niche biologics to front-line primary care.
Read more...